|
Models
|
Cofactors
|
Femoral neck BMD
|
Lumbar BMD
|
|---|
| | |
BMD variation
|
P
|
BMD variation
|
P
|
|---|
|
1
|
Infliximab
|
0.027
|
0.001
|
0.030
|
0.001
|
|
2
|
Infliximab
|
0.027
|
0.001
|
0.031
|
0.001
|
| |
Male sex
|
-0.009
|
0.40
|
0.008
|
0.47
|
| |
Age
|
0.002
|
0.56
|
0.005
|
0.09
|
|
3
|
Infliximab
|
0.020
|
0.03
|
0.033
|
0.001
|
| |
Male sex
|
-0.014
|
0.22
|
0.006
|
0.64
|
| |
Age
|
0.001
|
0.86
|
0.005
|
0.15
|
| |
Patients on steroids
|
-0.012
|
0.20
|
-0.001
|
0.92
|
|
4
|
Infliximab
|
0.023
|
0.01
|
0.034
|
0.001
|
| |
Male
|
-0.014
|
0.22
|
0.006
|
0.61
|
| |
Age
|
-0.001
|
0.90
|
-0.001
|
0.88
|
| |
Menopause
|
0.005
|
0.75
|
0.022
|
0.20
|
| |
Patients on steroids
|
-0.010
|
0.29
|
-0.002
|
0.87
|
| |
DAS28
|
-0.008
|
0.04
|
-0.006
|
0.17
|
|
5
|
Infliximab
|
0.023
|
0.02
|
0.035
|
0.001
|
| |
Male
|
-0.015
|
0.20
|
0.007
|
0.58
|
| |
Age
|
-0.001
|
0.85
|
0.000
|
0.95
|
| |
Menopause
|
0.006
|
0.70
|
0.020
|
0.25
|
| |
Patients on steroids
|
-0.009
|
0.37
|
-0.004
|
0.65
|
| |
DAS28
|
-0.008
|
0.05
|
-0.006
|
0.15
|
| |
Patients on biphosphonates
|
-0.012
|
0.29
|
0.022
|
0.07
|
|
6
|
Infliximab
|
0.028
|
0.002
|
0.041
|
0.001
|
| |
Male
|
-0.007
|
0.53
|
0.010
|
0.39
|
| |
Age
|
-0.002
|
0.61
|
0.002
|
0.63
|
| |
Patients on steroids
|
-0.008
|
0.35
|
-0.001
|
0.91
|
| |
DAS28
|
-0.007
|
0.06
|
-0.007
|
0.10
|
| |
Baseline BMD values
|
-0.042
|
0.16
|
-0.080
|
0.01
|
- All 189 patients were included in several analysis of covariance models for bone mineral density (BMD) variations (final values minus initial values) to analyze the effect of cofactors (continuous variables and discrete variables) on that of infliximab. DAS, Disease Activity Score.
